Adjunctive D-Cycloserine in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

December 24, 2020

Study Completion Date

December 24, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

D-cycloserine

Daily oral D-cycloserine 100mg during the blinded phase (10 days).

DEVICE

Transcranial Magnetic Stimulator

Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.

DRUG

Placebo oral capsule

Daily oral placebo during the blinded phase (10 days).

Trial Locations (1)

T2N1N4

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER

NCT03937596 - Adjunctive D-Cycloserine in Major Depressive Disorder | Biotech Hunter | Biotech Hunter